Crossmark

Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis

Crossref DOI link: https://doi.org/10.1186/s13023-022-02276-y

Published Online: 2022-04-04

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Dong

Chen, Xi-Hua

Wei, Ang

Zhou, Chun-Ju

Zhang, Xue

Ma, Hong-Hao

Lian, Hong-Yun

Zhang, Li

Zhang, Qing

Huang, Xiao-Tong

Wang, Chan-Juan

Yang, Ying

Liu, Wei

Wang, Tian-You

Li, Zhi-Gang

Cui, Lei https://orcid.org/0000-0002-7611-1431
Zhang, Rui
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82070202, 82141119)
License Information

Text and Data Mining valid from 2022-04-04

Version of Record valid from 2022-04-04
More Information

Article History

Received: 7 November 2021

Accepted: 27 February 2022

First Online: 4 April 2022

Declarations

:

: This study was approved by the Beijing Children’s Hospital Institutional Review Board and was conducted in accordance with The Declaration of Helsinki. Informed consents were obtained from guardians of the patients.

: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below